I-123 Diagnostic Thyroid Tumor Whole-Body Scanning with Imaging at 6, 24, and 48 Hours

  title={I-123 Diagnostic Thyroid Tumor Whole-Body Scanning with Imaging at 6, 24, and 48 Hours},
  author={Stephen K. Gerard and Ralph R. Cavalieri},
  journal={Clinical Nuclear Medicine},
Purpose The use of I-123 in lieu of I-131 for diagnostic whole-body thyroid tumor scanning (DxRaI) in patients with differentiated thyroid cancer obviates the risk for stunning and affords significantly improved image quality. Because of the shorter half-life (13 hours) of I-123, images have been acquired primarily 6 or 24 hours after injection, potentially decreasing the sensitivity for detecting weakly avid thyroid tumor or remnant. Materials and Methods The authors evaluated the use of 111… 
Whole-body thyroid tumor 123I scintigraphy.
  • S. Gerard
  • Medicine
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 2003
The authors' experience showed that, in conjunction with their higher-dosage scheme, 48-h images yielded a higher target-to-background activity at sites of differentiated thyroid tissue, either tumor or remnant, than did images obtained at 24 or 6 h, which supports the suggestion that using larger doses of 123I and a later imaging time should improve diagnostic sensitivity.
Comparisons of I-123 diagnostic and I-131 post-treatment scans for detecting residual thyroid tissue and metastases of differentiated thyroid cancer
Diagnostic scanning with relatively low dose I-123 is not always predictive of subsequent therapeutic I-131 uptake, especially for lymph node and lung metastases of differentiated thyroid cancer.
A Comparison Between Diagnostic I-123 and Posttherapy I-131 Scans in the Detection of Remnant and Locoregional Thyroid Disease
The use of diagnostic I-123 pretherapy scintigraphy seems to be superior in many patients to posttherapy I-131 imaging obtained at 7 days in detecting locoregional metastases or remnant in postsurgical patients.
Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement
123I scanning is comparable to high-dose 131I post-treatment imaging in thyroid carcinoma patients, and 123I offers excellent image quality as a diagnostic agent.
I-123 Whole Body Scanning: Case Report and Discussion
The evidence strongly suggests that I-123 is at least as accurate for diagnostic whole body imaging as I-131 for differentiated thyroid carcinoma, with special reference to accuracy and the effect thereon of technical factors.
Tc-99m imaging in thyroidectomized differentiated thyroid cancer patients immediately before I-131 treatment
It is suggested that Tc-99m imaging not only serves as an alternative to low-dose I-131 scanning in the low-risk post-thyroidectomy patients but also provides a clue for the subsequent I- 131 therapeutic dosage and even for the outcome prediction.
Impact of Post-Thyroidectomy I-123 Versus I-131 Whole Body Scan on the Outcome of Radioactive Iodine ( I-131 ) Ablation for Differentiated Thyroid Carcinoma
  • Sayed
  • Medicine, Biology
  • 2015
The aim of the current study was to assess the impact of postthyroidectomy I-123 versus I-131 Whole Body Scan (WBS) on the outcome of I- 131 ablation for DTC, and found a significantly higher successful ablation rate among patients studied with I- 123 WBS compared to those studied withI-131 WBS before radioiodine ablation.
The management of differentiated thyroid cancer using 123I for imaging to assess the need for 131I therapy
High-dose 123I imaging is the correct predictor of the 131I post-therapy scan findings in most cases, at an administered activity that avoids stunning.
Optimal Time for 124I PET/CT Imaging in Metastatic Differentiated Thyroid Cancer.
124I PET/CT with dual-time-point imaging was superior to any single- Time Point imaging (97% vs 87%) and the median ACRmean/AA was highest at 24 and 48 h, and the Median lesion-to-bkg ratio was variable for different lesion locations.
Initial staging of differentiated thyroid carcinoma: continued utility of posttherapy 131I whole-body scintigraphy.
In patients with newly diagnosed differentiated thyroid cancer who had undergone thyroidectomy and ( 131)I ablation, posttherapy whole-body scintigraphy revealed new IAFs in 18% and clinical upstaging occurred in 10% of patients compared with pretherapy ( 123)I whole- body scintigraphicy, indicating incremental clinically relevant information is provided.


Superiority of Iodine-123 Compared with Iodine-131 Scanning for Thyroid Remnants in Patients with Differentiated Thyroid Cancer
I-123 imaging may prove to be the preferred procedure in such settings in patients with differentiated thyroid cancer undergoing ablation for thyroid remnants after initial surgery.
The usefulness of iodine-123 whole-body scans in evaluating thyroid carcinoma and metastases.
It is found that iodine-123 is effective in demonstrating residual thyroid tissue, thyroid carcinoma and metastases, and recommend its use for whole-body iodine scans since it does not cause thyroid stunning.
Value of Post-Therapy Whole-Body I-131 Imaging in the Evaluation of Patients with Thyroid Carcinoma Having Undergone High-Dose I-131 Therapy
Post-therapy whole-body I-131 images demonstrated either additional findings, such as unsuspected cervical node or pulmonary uptake, or more accurate localization of abnormalities seen on the diagnostic study, which would suggest reevaluation of the advisability of using 1-2 mCi doses of I- 131 for diagnostic whole- body imaging.
Thyroid stunning after (131)I diagnostic whole-body scanning.
Diagnostic whole-body scanning can be performed effectively with a 185-MBq (5-mCi) dose of 131 I 72 h before radioiodine ablation with no evidence of, and therefore no concern for, thyroid stunning, according to Cholewinski et al.
Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
Diagnostic whole-body scanning can be performed effectively with a 185-MBq (5 mCi) dose of (131)I 72 h before radioiodine ablation without concern for thyroid stunning.
Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma
A diagnostic dose of 185 MBq 131I decreases thyroid uptake for several weeks after administration and can impair immediate subsequent 131I therapy; 123I is slightly less sensitive than 131I in identifying thyroid remnants; and the need to scan for thyroid remnants remains to be confirmed.
Nuclear imaging in the management of thyroid carcinoma.
  • R. Cavalieri
  • Medicine, Biology
    Thyroid : official journal of the American Thyroid Association
  • 1996
Several tumor-seeking radioisotopic agents other than radioiodine have shown promise for improving the detection of metastases, and some of these agents offer a useful adjunct to 131I in the management of selected patients, particularly in those with suspected metastatic disease and negative 131I scans.
74 MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancer.
74 MBq 131I seldom interferes with subsequent therapy and seldom underestimates the extent of thyroid cancer, and would appear to be an appropriate dose for diagnostic scintigraphy.
The significance of 1-131 scan dose in patients with thyroid cancer: determination of ablation: concise communication.
It is concluded that a 2-mCi or lower dose of I-131 is inadequate in evaluating residual iodine-avid tissue visually in patients with differentiated thyroid cancer and it may be appropriate to define ablation visually as well as clinically, with further studies directed toward determining a treatment rationale.
Radioiodine uptake in thyroid cancer patients after diagnostic application of low-dose 131I.
Results show that a diagnostic dose of 74 MBq 131I markedly reduces thyroid uptake of an ablation dose of 131I, which should be taken into account during radiation dose planning whenever a quantitative dosimetric study is to be performed.